Skip to Content

Viibryd Approval History

Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD).

Development History and FDA Approval Process for Viibryd

Mar 16, 2015Approval Actavis Receives FDA Approval for Viibryd (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose
Jan 24, 2011Approval FDA Approves Viibryd to Treat Major Depressive Disorder
Nov 16, 2010Clinical Data, Inc. Announces Issuance of New U.S. Patent for Vilazodone
May 24, 2010Clinical Data, Inc. Announces FDA Acceptance of New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder
Mar 23, 2010Clinical Data Submits NDA for Depression Compound

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.